| Literature DB >> 31856367 |
Chiara Baglioni1,2, Ellemarije Altena3, Bjørn Bjorvatn4, Kerstin Blom5, Kristoffer Bothelius6, Alessandra Devoto7, Colin A Espie8, Lukas Frase1, Dimitri Gavriloff8, Hion Tuuliki9,10, Andrea Hoflehner11, Birgit Högl11, Brigitte Holzinger12, Heli Järnefelt13,14, Susanna Jernelöv5,15, Anna F Johann1,16, Caterina Lombardo17, Christoph Nissen18, Laura Palagini19, Geert Peeters20, Michael L Perlis21, Donn Posner22, Angelika Schlarb23, Kai Spiegelhalder1, Adam Wichniak24, Dieter Riemann1.
Abstract
Insomnia, the most prevalent sleep disorder worldwide, confers marked risks for both physical and mental health. Furthermore, insomnia is associated with considerable direct and indirect healthcare costs. Recent guidelines in the US and Europe unequivocally conclude that cognitive behavioural therapy for insomnia (CBT-I) should be the first-line treatment for the disorder. Current treatment approaches are in stark contrast to these clear recommendations, not least across Europe, where, if any treatment at all is delivered, hypnotic medication still is the dominant therapeutic modality. To address this situation, a Task Force of the European Sleep Research Society and the European Insomnia Network met in May 2018. The Task Force proposed establishing a European CBT-I Academy that would enable a Europe-wide system of standardized CBT-I training and training centre accreditation. This article summarizes the deliberations of the Task Force concerning definition and ingredients of CBT-I, preconditions for health professionals to teach CBT-I, the way in which CBT-I should be taught, who should be taught CBT-I and to whom CBT-I should be administered. Furthermore, diverse aspects of CBT-I care and delivery were discussed and incorporated into a stepped-care model for insomnia.Entities:
Keywords: CBT-I; European CBT-I Academy; cognitive behavioural therapy for insomnia; insomnia; stepped-care
Mesh:
Year: 2019 PMID: 31856367 DOI: 10.1111/jsr.12967
Source DB: PubMed Journal: J Sleep Res ISSN: 0962-1105 Impact factor: 3.981